Dr. Driehuys was a co-inventor of hyperpolarized gas MRI while completing his Doctorate in atomic Physics at Princeton University in the 1990’s. In 1996, Dr. Driehuys helped to start MITI, a company founded to commercialize hyperpolarized gas technology. In 1999, Dr. Driehuys became CEO of the company, managed its acquisition by Amersham Health and he remained with the company as Director of the Research Triangle Park Facility until 2003. In this senior management position he oversaw all hyperpolarized gas physics and applications research. He served on the Amersham global imaging management team, which was broadly responsible for the company’s diagnostic imaging research pipeline, spanning all modalities and disease areas. In 2004, Dr. Driehuys returned to academia where is now an Associate Professor of Radiology, Medical Physics, and Biomedical Engineering at Duke University. His research program has been focused on driving the clinical translation of hyperpolarized 129Xe MRI, and exploiting the unique properties of this atom for molecular imaging.
Dr. Driehuys completed his post-doctoral work and Ph.D. in atomic physics at Princeton University after receiving his BA summa cum laude in physics from Franklin & Marshall College in Lancaster, PA. He has authored more than 50 publications in the areas of hyperpolarization physics and biological applications. He holds 32 granted US patents and is a co-recipient of the Thomas Alva Edison Patent Award, as well as the Tibbetts Award for Outstanding small business scientific accomplishment.
Mr. Hullihen has over 30 years in medical imaging with GEC-Picker International, and Marconi Medical systems creating their CT and MR businesses before moving to start m2m imaging with Amphion Innovations. He has broad experience in medical imaging technology management, engineering, sales and marketing, manufacturing, and business development, in the US and internationally. He served as the CEO of m2m Imaging since its formation.
Mr. Hullihen holds a BS in Electrical Engineering from Western Michigan University, and an MBA from the Weatherhead School of Case Western Reserve University.
Mr. West’s began his career with Fortune 200 FMC Corporation in the 1980’s, where he was Director of Marketing and Business Development for a division that supplied excipient products to the pharmaceutical industry. Since that time, Mr. West has been involved at a senior level with 5 successful new companies in the medical technology field. He held senior management positions at three venture-capital backed start-ups, including Vice President of Sales, Marketing and Business Development at Embrex, Inc. a drug delivery company that went public and then was acquired by Pfizer; COO at VetInsite, a health care information technology company that was acquired by MediMedia; and Biolex, a transgenic protein company, where he was a founder and the first President/ COO. The company raised more than $180 million in venture capital and was acquired by Synthon. Mr. West has also led the US subsidiaries of two European medical device companies as they entered the US market, including Curasan AG and Tem International. As President of each of these US companies, Mr. West built and managed the US organizations, growing them into multi-million dollar subsidiaries with direct sales forces to physician offices and hospitals.
Mr. West holds a B.S. degree in chemical engineering from Cornell University and an MBA from the Wharton School of the University of Pennsylvania.
For the past ten years, Dr. Emami has been both a user and developer of HP gas technology and a leader of a number of HP gas projects at the Radiology Department of the University of Pennsylvania, a leading center for HP gas MRI. These projects have included a project to develop a multi-breath ventilation imaging protocol to measure specific ventilation distribution in lungs, and a passive HP gas delivery device, which enables metered administration consecutive HP gas breaths to conscious human subjects (patent pending).
While at the University of Pennsylvania, Dr. Emami was a Fellow of the University’s technology transfer center and Dr. Emami was also a co-founder of Spinhance, LLC, a company that designed and built the first fully automated 3He polarizer system to support a multi-site COPD ancillary study to be funded by NIH. Since joining Polarean Imaging plc. in 2012, he has directed all aspects of Polarean Imaging plc.’s technical efforts, including building, upgrading, installing, training and servicing 129Xe hyperpolarization systems around the world.
Dr. Emami holds a BS in mechanical engineering from KNT University of Technology (Tehran), an MS in bioengineering and a PhD in electrical and systems engineering; both form University of Pennsylvania.